Salmones Camanchaca S.A. (SNSE:SALMOCAM)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	19.19	13.92	-5.99	44.7	-9.36	-31.63
Depreciation & Amortization	27.38	21.71	18.88	17.76	16.26	15.48
Other Operating Activities	29.37	21.15	-13.79	13.53	-25.81	26.34
Operating Cash Flow	75.94	56.78	-0.91	76	-18.92	10.19
Operating Cash Flow Growth	-	-	-	-	-	-41.96%
Capital Expenditures	-27.01	-24.12	-20.26	-28.8	-14.87	-22.85
Sale of Property, Plant & Equipment	0.16	0.16	0.06	0.14	0.33	0.05
Other Investing Activities	-	-	-	-	-	0.01
Investing Cash Flow	-26.85	-23.96	-20.19	-28.66	-14.54	-22.8
Short-Term Debt Issued	-	8	21	-	4	-
Long-Term Debt Issued	-	-	28	-	35	29
Total Debt Issued	8	8	49	-	39	29
Long-Term Debt Repaid	-	-26.5	-	-58	-4	-4
Net Debt Issued (Repaid)	-49.5	-18.5	49	-58	35	25
Issuance of Common Stock	-	-	-	0.01	22.77	-
Common Dividends Paid	-	-	-24.31	-	-	-16.85
Financing Cash Flow	-49.5	-18.5	24.69	-57.99	57.77	8.15
Foreign Exchange Rate Adjustments	0.39	-0.63	-0.11	-0.72	-1.18	-0.37
Net Cash Flow	-0.03	13.69	3.48	-11.38	23.13	-4.83
Free Cash Flow	48.93	32.66	-21.16	47.2	-33.79	-12.66
Free Cash Flow Margin	12.50%	8.07%	-5.98%	12.65%	-11.51%	-4.96%
Free Cash Flow Per Share	0.66	0.44	-0.28	0.64	-0.46	-0.19
Cash Interest Paid	12.63	12.41	8.63	6.46	3.98	3.64
Cash Income Tax Paid	0	0	0.03	0	0.04	7.83
Levered Free Cash Flow	50.87	31.75	-30.51	32.26	-26.33	-8.53
Unlevered Free Cash Flow	58.3	39.57	-24.41	36.52	-23.45	-6.23

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.